Brian Lee McClune DO
Hematologic Oncology
Associate Professor, Medicine, University of Utah
Join to View Full Profile
1950 Circle of Hope DrSalt Lake City, UT 84112
Phone+1 801-585-0100
Dr. McClune is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of TennesseeFellowship, Hematology and Medical Oncology, 2003 - 2006
Johns Hopkins UniversityResidency, Internal Medicine, 2000 - 2003
Kansas City University of Medicine and Biosciences College of Osteopathic MedicineClass of 2000
Certifications & Licensure
UT State License 2019 - 2026
KS State License 2018 - 2020
MN State License 2006 - 2018
TN State License 2003 - 2011
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Autologous Transplant for Multiple Myeloma Start of enrollment: 2004 Apr 20
- Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403) Start of enrollment: 2007 Aug 01
- Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Start of enrollment: 2006 Dec 19
- Join now to see all
Publications & Presentations
PubMed
- Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressiv...Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary N Steinbach, Samuel Shewan
Leukemia & Lymphoma. 2024-09-01 - 3 citationsMultiple Myeloma in Young Patients: A Scoping Review.Mary Steinbach, Karun Neupane, Muhammad Aziz, Wade Lee-Smith, Kelley Julian
Clinical Lymphoma, Myeloma & Leukemia. 2024-01-01 - Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials.Poorva Bindal, Mimi Najjar, Kelly Koehn, Amandeep Godara, Douglas W Sborov
Leukemia & Lymphoma. 2023-05-11
Journal Articles
- Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple MyelomaBrian McClune, DO, JAMA Oncology
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
